Comparison · NCT00423670-d8d18217
Arm 4 and Arm 5. PEG + RBV + BOC (48 Weeks) vs Arm 2 and Arm 3. PEG + RBV + BOC (28 Weeks): Number of Participants With SVR Based on Duration of Boceprevir Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 4 and Arm 5. PEG + RBV + BOC (48 Weeks) vs Arm 2 and Arm 3. PEG + RBV + BOC (28 Weeks): Number of Participants With SVR Based on Duration of Boceprevir Treatment. Trial comparisons, record NCT00423670-d8d18217. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00423670-d8d18217
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.709 | 0.643 | 0.767 | wilson | |
| Risk in group 2 | 0.552 | 0.485 | 0.618 | wilson | |
| Risk difference, group 1 minus group 2 | 0.156 | 0.0636 | 0.245 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.28 | 1.1 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | 1.97 | 1.31 | 2.96 | log | |
| Number needed to treat, for one more participant with the outcome on Arm 4 and Arm 5. PEG + RBV + BOC (48 Weeks) than on Arm 2 and Arm 3. PEG + RBV + BOC (28 Weeks) | 6.4 | 4.08 | 15.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 4 and Arm 5. PEG + RBV + BOC (48 Weeks) | PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) with or without a 4 weeks lead with boceprevir (800 mg TID) for 48 weeks. | 146 | 206 | OG000 |
| Group 2 | Arm 2 and Arm 3. PEG + RBV + BOC (28 Weeks) | PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) with or without a 4 weeks lead with boceprevir (800 mg TID) for 28 weeks. | 116 | 210 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With SVR Based on Duration of Boceprevir Treatment
- Description
Number of participants with SVR (undetectable plasma HCV-RNA at FW 24 up to EOF). Participants from treatment arms receiving boceprevir for 28-weeks (Arm 2 and Arm 3) were pooled, and those receiving boceprevir for 48-weeks (Arm 4 and Arm 5) were pooled for the analysis.~Participants missing data at FW 24 were considered to achieve SVR if~1. he/she had undetectable HCV-RNA at FW 12 or later~2. he/she returned later to the study center and had undetectable HCV-RNA.~HCV-RNA in plasma samples was detected with an RT-PCR assay. The LLD for the assay was 29 IU/mL.
- Time frame
- From FW 24 up to EOF
- Population
- Intent-to-Treat (ITT) population: All randomized participants who received at least one dose of any study medication (PegIntron, ribavirin, or boceprevir).
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)
- NCT number
- NCT00423670
- Phases
- PHASE2
- Conditions
- Chronic Hepatitis C
- Interventions
- boceprevir (SCH 503034), peginterferon-alfa 2b (PegIntron), ribavirin, ribavirin (low-dose)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2011-06-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00423670?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00423670-d8d18217